000181329 001__ 181329
000181329 005__ 20240301125646.0
000181329 0247_ $$2doi$$a10.1158/1078-0432.CCR-17-2007
000181329 0247_ $$2pmid$$apmid:29051321
000181329 0247_ $$2pmc$$apmc:PMC5754253
000181329 0247_ $$2ISSN$$a1078-0432
000181329 0247_ $$2ISSN$$a1557-3265
000181329 0247_ $$2altmetric$$aaltmetric:27667601
000181329 037__ $$aDKFZ-2022-01956
000181329 041__ $$aEnglish
000181329 082__ $$a610
000181329 1001_ $$0P:(DE-He78)79e92bc6260b7a24abe4daf4378bf19c$$aMöhrmann, Lino$$b0$$eFirst author$$udkfz
000181329 245__ $$aLiquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
000181329 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2018
000181329 3367_ $$2DRIVER$$aarticle
000181329 3367_ $$2DataCite$$aOutput Types/Journal article
000181329 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661174552_31348
000181329 3367_ $$2BibTeX$$aARTICLE
000181329 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181329 3367_ $$00$$2EndNote$$aJournal Article
000181329 500__ $$aPOF Topic: 317
000181329 520__ $$aPurpose: Blood-based liquid biopsies offer easy access to genomic material for molecular diagnostics in cancer. Commonly used cell-free DNA (cfDNA) originates from dying cells. Exosomal nucleic acids (exoNAs) originate from living cells, which can better reflect underlying cancer biology.Experimental Design: Next-generation sequencing (NGS) was used to test exoNA, and droplet digital PCR (ddPCR) and BEAMing PCR were used to test cfDNA for BRAFV600, KRASG12/G13, and EGFRexon19del/L858R mutations in 43 patients with progressing advanced cancers. Results were compared with clinical testing of archival tumor tissue and clinical outcomes.Results: Forty-one patients had BRAF, KRAS, or EGFR mutations in tumor tissue. These mutations were detected by NGS in 95% of plasma exoNA samples, by ddPCR in 92% of cfDNA samples, and by BEAMing in 97% cfDNA samples. NGS of exoNA did not detect any mutations not present in tumor, whereas ddPCR and BEAMing detected one and two such mutations, respectively. Compared with patients with high exoNA mutation allelic frequency (MAF), patients with low MAF had longer median survival (11.8 vs. 5.9 months; P = 0.006) and time to treatment failure (7.4 vs. 2.3 months; P = 0.009). A low amount of exoNA was associated with partial response and stable disease ≥6 months (P = 0.006).Conclusions: NGS of plasma exoNA for common BRAF, KRAS, and EGFR mutations has high sensitivity compared with clinical testing of archival tumor and testing of plasma cfDNA. Low exoNA MAF is an independent prognostic factor for longer survival. Clin Cancer Res; 24(1); 181-8. ©2017 AACR.
000181329 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000181329 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181329 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000181329 650_7 $$2NLM Chemicals$$aCell-Free Nucleic Acids
000181329 650_7 $$2NLM Chemicals$$aKRAS protein, human
000181329 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aEGFR protein, human
000181329 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aErbB Receptors
000181329 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aBRAF protein, human
000181329 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProto-Oncogene Proteins B-raf
000181329 650_7 $$0EC 3.6.5.2$$2NLM Chemicals$$aProto-Oncogene Proteins p21(ras)
000181329 650_2 $$2MeSH$$aAdult
000181329 650_2 $$2MeSH$$aAged
000181329 650_2 $$2MeSH$$aBiomarkers, Tumor
000181329 650_2 $$2MeSH$$aCell-Free Nucleic Acids
000181329 650_2 $$2MeSH$$aErbB Receptors: blood
000181329 650_2 $$2MeSH$$aErbB Receptors: genetics
000181329 650_2 $$2MeSH$$aExosomes
000181329 650_2 $$2MeSH$$aFemale
000181329 650_2 $$2MeSH$$aGenetic Testing
000181329 650_2 $$2MeSH$$aHumans
000181329 650_2 $$2MeSH$$aLiquid Biopsy: methods
000181329 650_2 $$2MeSH$$aMale
000181329 650_2 $$2MeSH$$aMiddle Aged
000181329 650_2 $$2MeSH$$aMutation
000181329 650_2 $$2MeSH$$aNeoplasm Grading
000181329 650_2 $$2MeSH$$aNeoplasm Staging
000181329 650_2 $$2MeSH$$aNeoplasms: blood
000181329 650_2 $$2MeSH$$aNeoplasms: diagnosis
000181329 650_2 $$2MeSH$$aNeoplasms: mortality
000181329 650_2 $$2MeSH$$aPatient Outcome Assessment
000181329 650_2 $$2MeSH$$aProto-Oncogene Proteins B-raf: blood
000181329 650_2 $$2MeSH$$aProto-Oncogene Proteins B-raf: genetics
000181329 650_2 $$2MeSH$$aProto-Oncogene Proteins p21(ras): blood
000181329 650_2 $$2MeSH$$aProto-Oncogene Proteins p21(ras): genetics
000181329 650_2 $$2MeSH$$aSurvival Analysis
000181329 7001_ $$aHuang, Helen J$$b1
000181329 7001_ $$aHong, David S$$b2
000181329 7001_ $$aTsimberidou, Apostolia M$$b3
000181329 7001_ $$aFu, Siqing$$b4
000181329 7001_ $$aPiha-Paul, Sarina A$$b5
000181329 7001_ $$aSubbiah, Vivek$$b6
000181329 7001_ $$aKarp, Daniel D$$b7
000181329 7001_ $$aNaing, Aung$$b8
000181329 7001_ $$aKrug, Anne$$b9
000181329 7001_ $$aEnderle, Daniel$$b10
000181329 7001_ $$aPriewasser, Tina$$b11
000181329 7001_ $$aNoerholm, Mikkel$$b12
000181329 7001_ $$aEitan, Erez$$b13
000181329 7001_ $$aCoticchia, Christine$$b14
000181329 7001_ $$aStoll, Georg$$b15
000181329 7001_ $$aJordan, Lisa-Marie$$b16
000181329 7001_ $$aEng, Cathy$$b17
000181329 7001_ $$aKopetz, E Scott$$b18
000181329 7001_ $$aSkog, Johan$$b19
000181329 7001_ $$aMeric-Bernstam, Funda$$b20
000181329 7001_ $$aJanku, Filip$$b21
000181329 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-17-2007$$gVol. 24, no. 1, p. 181 - 188$$n1$$p181 - 188$$tClinical cancer research$$v24$$x1078-0432$$y2018
000181329 909CO $$ooai:inrepo02.dkfz.de:181329$$pVDB
000181329 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79e92bc6260b7a24abe4daf4378bf19c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181329 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000181329 9141_ $$y2018
000181329 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2019$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000181329 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2019$$d2021-02-03
000181329 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x0
000181329 980__ $$ajournal
000181329 980__ $$aVDB
000181329 980__ $$aI:(DE-He78)G100-20160331
000181329 980__ $$aUNRESTRICTED